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Abstract
Background: Malaria is reportedly receding in different epidemiological settings, but local long-term surveys are
limited. At Mlomp dispensary in south-western Senegal, an area of moderate malaria transmission, year-round,
clinically-suspected malaria was treated with monotherapy as per WHO and national policy in the 1990s. Since
2000, there has been a staggered deployment of artesunate-amodiaquine after parasitological confirmation; this
was adopted nationally in 2006.
Methods: Data were extracted from clinic registers for the period between January 1996 and December 2010,
analysed and modelled.
Results: Over the 15-year study period, the risk of malaria decreased about 32-times (from 0.4 to 0.012 episodes
person-year), while anti-malarial treatments decreased 13-times (from 0.9 to 0.07 treatments person-year) and
consultations for fever decreased 3-times (from 1.8 to 0.6 visits person-year). This was paralleled by changes in the
age profile of malaria patients so that the risk of malaria is now almost uniformly distributed throughout life, while
in the past malaria used to concern more children below 16 years of age.
Conclusions: This study provides direct evidence of malaria risk receding between 1996-2010 and becoming equal
throughout life where transmission used to be moderate. Infection rates are no longer enough to sustain
immunity. Temporally, this coincides with deploying artemisinin combinations on parasitological confirmation, but
other contributing causes are unclear.
Background
The Global Malaria Action Plan [1] aims at (i) providing
universal coverage (prevention plus case management)
by 2010; (ii) reducing the malaria burden and deaths by
50% in 2010, 75% in 2015 vs. 2000, (iii) eliminating
malaria in 8-10 countries by 2015; and (iv) eradicating
malaria in the long-term.
The foundations for this plan are that these objectives
can be achieved (as locally applicable) by making avail-
able and deploying at the same time interventions,
which have proved beneficial individually, including
insecticide-treated nets (ITN), insecticide residual
spraying (IRS), and artemisinin-based combination ther-
apy (ACT).
While the Malaria Action Plan was being launched, a
Lancet commentary [2] found that, in the previous 10
years, some 80 papers had reported trends in malaria
incidence (increased in 15%, not changed in 14% and
decreased in 71%). The same Lancet issue published two
papers reporting decreasing malaria burden in the Gam-
bia and Kenya [3,4]. These general trends towards a
reduction of malaria were confirmed by the World
Health Organization (WHO) in the Malaria Report 2009
[5] and 2010 [6] and other papers [7,8].
Against this scenario, a central question is now to col-
lect the information which will allow properly docu-
menting and interpreting these trends across endemic
areas, while being cognisant that long-term trends are
notoriously difficult to interpret (likely to be multi-
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biases).
This was a facility-based study of malaria risk over a
period of 15 years during which malaria treatment pol-
icy changed from administering anti-malarial monother-
apy on clinical grounds to artemisinin combination on
parasitological confirmation.
Methods
Study area
Mlomp (between latitudes 12°36’ and 12°32’N and longi-
tudes 16°33’ and 16°37’E) is a village in the district of
Oussouye, south-western Senegal. Since 2000, the popu-
lation has been stable with about 7,600 inhabitants
[9,10] and was about 6,000 before [10]. The village has a
dispensary - a government peripheral health centre
reporting to the district medical officer in Oussouye; the
dispensary has one nurse, one technician and three
health workers and is run by a congregation. No private
pharmacies or drug sellers exist in the village.
Here, malaria is reportedly mesoendemic; transmission
of moderate intensity occurs year-round with a seasonal
peak during the rainy season (roughly July-December).
Updated information on transmission intensity and
entomological inoculation rates (EIR) is not available
(the latest study done in the late 1990’s report EIR of
~25 infected bites per person per year [11].
The malaria treatment policy in Senegal has been
chloroquine or quinine administered after clinical pre-
sumptive diagnosis until 2004. Following an interim pol-
icy of amodiaquine plus sulphadoxine/pyrimethamine
(SP), artesunate-amodiaquine (AS+AQ) became the
first-line treatment in 2006 and rapid diagnostic tests
(RDT) were made available from 2007 for the diagnosis
of malaria. After a clinical trial in 1999 [12], AS+AQ
was initially used for children under 10 in the rainy sea-
son and then extended to the whole population [13-15].
The implementation of the new policy (artesunate-amo-
diaquine after parasitological confirmation) and the pre-
vious practice (quinine or another drug on clinical
grounds) have coexisted during this period. The efficacy
and safety of artesunate-amodiaquine have been docu-
mented [13,15].
The age structure of the malaria cases in this area
remained stable over several years [15] and consistent
with other areas of similar endemicity in Senegal [16],
with the highest risk of malaria being between 6-15
years (57% of cases), that extends also later in life (8%
were 21-30, 7% 30 and above).
Data
Data on overall consultations for fever, malaria treat-
ments, parasitological test results and patients’ age were
extracted from the clinic registers of the dispensary of
the village of Mlomp for the period of 01/01/1996 to
31/12/2010.
Information on patient demography (age as date of
birth from the patient’s identity card or the health card
if a child, and sex), clinical signs (measured axillary
fever) and reasons for consulting, diagnosis and treat-
ment are recorded on a standard registry delivered by
the Ministry of Health. Registries are kept by the nurse
and filled daily, and inspected a monthly basis by the
district medical officer.
Parasitological diagnosis was by thick (counting 200
WBCs) and thin blood smear before 2007, and by HRP-
2 based RDT from 2007 (quality-controlled systemati-
cally by blood smear at the dispensary).
The rate of positive parasitological tests was applied to
the overall number of treatments to obtain the projected
malaria cases. The rates of treatments given after a posi-
tive, negative or no parasitological test were calculated
out of the number of treatments and the number of
consultations for fever. The number of AS+AQ treat-
ments was also divided by the number of treatments to
give the relevant rate.
Age (in months or years) was analysed both as a con-
tinuous variable and by age categories (0-5 years, 6-10,
11-15, 16-20, 21-30 and > 30). The distribution of age
throughout the years between patients with positive and
negative malaria tests was assessed using a general linear
model. The parasitological tests were either microscopy
(stained thin plus thick smear) or a RDT based on histi-
dine-rich protein II (HRP-II).
Counts of malaria treatments were reported per year
on aggregate and also specifically for each of the treat-
ments with quinine, AS+AQ, chloroquine and AQ+SP.
Age-dependent risk of malaria
Counts of positive parasitological tests were reported
and compared over the years for the age categories 0-5y,
6-10y, 11-15y, 12-15y, 16-20y, 21-30y and > 30y.
Parasitological tests count model
A count data model was used to evaluate the effect of
parasitological test results (positive or negative), age and
year on the count of parasitological tests done in
Mlomp. Count data were tested for over-dispersion
using the Lagrange multiplier test. The Poisson model
was used when no over-dispersion was found, otherwise
the negative binomial model was used. The model
accounted for patient’s age, year, interaction between
age and year (the effect of age nested into the year),
parasitological test result, its interaction with year and
its interaction with age and year. Age was first intro-
duced in the model as a continuous and subsequently as
a categorical variable with the group 0-5 years as the
reference.
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parasitological tests with a 95% confidence interval (95%
CI) was assessed with the age category 0-5y, the year
1996 and a negative parasitological test as the references
of the corresponding variables.
Malaria risk model
The odds of having parasitologically-confirmed malaria
were evaluated over the years by using a logistic model
for a positive parasitological test (i.e. positive vs. nega-
tive parasitological test as dependent variable), firstly
with the year and age considered independently, and
then with the interaction between them. The Odds
Ratio (OR) of a parasitological test outcome depending
on age were assessed for each year. The addition of a
quadratic term of age (age*age) in the model was not
significant, therefore, a linear relationship between age
(continuous) and the probability of positive parasitologi-
cal test was used.
Since (i) there was a significant interaction between
age and year in the model, and (ii) patients data are
independent from year to year, single models for each
year including age as continuous variable were used to
estimate the OR of malaria.
Results
Malaria burden in 1996-2010
Overall trends
Between January 1996 and December 2010, a total of
105,417 patients consulted for fever and 45,907 (44%)
received an anti-malarial treatment (whether on clinical
or parasitological confirmation); 30,685 (29% of all con-
sultations for fever) underwent parasitological confirma-
tion (either thin/thick smear or RDT) and 27,081 had
also age recorded (26%); 10,786 (24%) tested positive for
Plasmodium falciparum. The projected number of
malaria cases over the entire period was 18,528.
Over time, all these figures decreased steadily. Table 1
presents the yearly and Figure 1 the monthly records of
consultations for fever, anti-malarial treatments dis-
pensed and projected real (parasitologically-confirmed)
malaria cases during 1996-2010.
As an example, when comparing the years before the
start of the new malaria treatment practice (1996-1999)
to the period 2007-2010, the calculated risk of malaria
decreased approximately 32 times from ~0.4 to ~0.012
episodes person-year. Concomitantly, consultations for
fever decreased 3-times (from ~1.8 to 0.6 visits person-
year) and anti-malarial treatments decreased 13-times
(from ~0.9 to 0.07 treatments person-year) (Figure 2).
Malaria treatments and treatment practices
The number of malaria treatments was > 4,400/year
between 1996-2001 (peak in 1998 with 5,680 treat-
ments) and then started to decline steadily from 2002
(Table 2 and Figure 3). Four drugs (quinine 82%, AS
+AQ 9%, chloroquine 6%, and amodiaquine + SP 1%)
accounted for ~98% of all drugs used on either clinical
or parasitological grounds over the 15-year period.
Overall, 4,424 AS+AQ and 37,669 quinine treatments
were delivered from 1996 to 2009. Quinine use was
high (~80-95%) until 2003, then steadily decreasing
(but was still accounting for 38 of the 87 treatments in
Table 1 Yearly records of consultations for fever, anti-malarial treatments dispensed (on either clinical or
parasitological grounds) and projected real (parasitologically-confirmed) malaria cases in Mlomp during 1996-2009
Year Consultations for
fever
Anti-malarial
treatments
Projected Malaria
Cases
Parasitologically
Tested
Parasitological test result and age
recorded
(% positive)
1996 10270 4637 2237 2148 2129 48.2%
1997 11274 5743 3065 2379 2376 53.4%
1998 11006 5680 1857 2275 2221 32.7%
1999 9807 5635 2243 2414 2372 39.8%
2000 9361 5391 2474 3466 2488 45.9%
2001 7910 4432 2260 3362 2524 51.0%
2002 5596 2834 968 2259 2047 34.1%
2003 6040 2948 1212 3192 2707 41.1%
2004 6068 2781 870 2099 1799 31.3%
2005 5212 2673 724 2139 1853 27.1%
2006 4131 1092 254 1681 1343 23.2%
2007 5128 996 125 1628 1535 12.6%
2008 4485 885 201 850 848 22.8%
2009 4213 93 18 464 462 19.7%
2010 4916 87 20 381 377 23.1%
All 105417 45907 18528 30737 27081 37.5%
The table presents also the total number of parasitological tests done each year and their outcome.
RDT introduced in 2007.
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diaquine+SP was an interim recommendation of the
national malaria control programme (used here only in
2005-2006); AS+AQ is the current policy in Senegal
and its use has been steadily extending (69/93 and 49/
87 treatments in 2009 and 2010). In absolute terms,
the number of treatments is decreasing sharply.
The policy of treating parasitologically confirmed cases
with artesunate-amodiaquine was applied in 4,424 cases
(44% 4,424/10,147 of the parasitologically-confirmed
treatments). The annual number and proportions of AS
+AQ treatments of the total consultations and treatment
are presented in Figure 3.
From the clinical registries and the malaria cases pro-
jections it can be derived that during the 15 years under
study 27,379 malaria treatments dispensed (or ~60% of
all treatments) were not supported by a positive parasi-
tological test (test not done or negative).
Figure 1 Monthly records of consultations for fever, anti-malarial treatments dispensed (on either clinical or parasitological grounds)
and projected real (parasitologically-confirmed) malaria cases in Mlomp during 1996-2010.
Figure 2 Relative Risk (RR) of consulting for fever, receiving a
malaria treatment and having a parasitologically-proven
malaria attack expressed in person-year relative to 1996.
Table 2 Anti-malarial treatments provided
YEAR All
Treatments
AS +
AQ
QC Q A Q +
SP
Other
Treatments
1996 4637 0 4132 504 0 1
1997 5743 0 5438 303 0 2
1998 5680 0 5475 203 0 2
1999 5635 160 4930 379 0 166
2000 5391 259 4794 284 0 54
2001 4432 305 3981 99 0 47
2002 2834 408 2191 234 0 1
2003 2948 798 1823 324 0 3
2004 2781 625 1747 387 0 22
2005 2673 661 1347 80 358 227
2006 1092 401 576 9 30 76
2007 996 280 697 1 0 18
2008 885 409 476 0 0 0
2009 93 69 24 0 0 0
2010 87 49 38 0 0 0
All 45907 4424 37669 2807 388 619
AS+AQ = artesunate+amodiaquine; Q = quinine; CQ = chloroquine; AQ+SP =
amodiaquine + sulphadoxine/pyrimethamine. The other treatments were: SP,
AQ, artemether-lumefantrine, AS-SP, AS or AS-mefloquine.
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Figure 4 shows the proportion of parasitologically-posi-
tive cases of fever by age-group in 1996-2010. The age
group 0-5y declined steadily throughout the entire study
period; the 6-10y declined slightly; the 11-15y remained
stable; the 16-20y, 21-30y and > 30y all increased.
The mean age of the malaria-positive patients increased
steadily from 13.5 years in 1996 to 21.1 in 2010, while it
fluctuated over time for the negatives, with similar values
in 2010 (23.5 years) and 1996 (19.8 years) (Figure 5). The
general linear model used to explain age by the time per-
iod under study and the parasitological test results showed
a significant difference in the evolution of age during
1996-2010 between the malaria-positive and -negative
subjects (p < 0.001 for year, tests and interaction).
Parasitological test count model
From the negative binomial model of the count of
parasitological tests, the interaction between test result
and age showed that in 1996 all age categories had a
lower risk of being tested for malaria (irrespective of
the result) than the 0-5y. The interaction between test
results and year showed that, overall, the risk of having
a negative test was higher than that of a positive test,
at all times (blue line in Figure 6). Compared to the
risk of a positive test in 1996, the risk of a positive test
(green line in Figure 6) became consistently lower
(upper 95%CI of the RR < 1) starting from 2004, while
this happened starting in 2008 for a negative test (red
line in Figure 6).
When adding the interaction between year and age to
the model, the results obtained for each age category
over the years (Table 3) were similar to the above-
described overall trends.
Figure 7 is based on the results of the interaction
between year and age, and shows the RR of a positive
parasitological test for each year of the period 1996-
2010 for the different age categories vs. the age group
0-5y. The frequency of parasitological tests showed
overall a similar trend for the 6-10y and 11-15y age
categories over the years with occasionally significant
RRs (Table 4) around the identity value (= 1) with a
small increase in the period 2008-2010. The other
three age categories showed a constant increase from
2001 to reach RRs > 1 for the 16-20y and > 30y age
categories in 2010. Overall, these results show that,
while in the past an age > 16 years had a lower risk
for a positive malaria test, more recently the risk has
become very similar across all ages.
Figure 4 Proportion parasitologically-positive malaria cases by age classes per year over the period 1996-2009.
Figure 3 Anti-malarial treatments dispensed at the Mlomp out-
patient clinic.
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The logistic model of the risk of a positive parasitologi-
cal test included the age of the subjects and the year of
examination. The interaction was significant in the
model. The models estimated the OR of positive parasi-
tological test between 1-35 years of age by 1-year incre-
ments, and then to 70 years by five-year increments.
This allows an analysis of the pattern of ORs change
with increasing age.
The models showed a significant age effect from 1996
to 2003. The ORs were all decreasing regularly from 1y
to 70y expressing a decreasing risk of positive parasito-
logical test with increasing age. Between 2004 and 2010
with the exception of the year 2007 (risk increasing with
age), age was no longer significant in the models. Over-
all, these results concur to show that in the past few
years, the risk of malaria has become the same through-
out life.
Discussion
This study is based on over 45,000 cases of suspected
malaria over 15 years at a rural dispensary in an area
where malaria used to be mesoendemic and of moderate
transmission intensity. Results document the decreased
burden of malaria and fevers between 1996-2010 and
the concurrent increase in the age of malaria patients.
Together, these variations indicate reduced malaria
transmission.
The 32-fold drop in the calculated risk of malaria was
paralleled by changes in the age profile of malaria
patients, so that the risk of malaria is now almost uni-
formly distributed throughout life, while in the past
malaria used to concern more children under 16 years
of age.
The age-dependent risk of malaria and its clinical pre-
sentation (uncomplicated and or severe) varies with
transmission intensity. Marked differences in the num-
ber of malaria attacks at different ages occur in varying
epidemiological settings (reviewed in Lalloo et al [17]).
Obviously, intensity of transmission and number of
challenges over time determine the susceptibility to
malaria infection and disease, as a function of building
immunity. The age profiles of malaria cases vary greatly
Figure 6 Relative Risk (RR) of a positive or negative
parasitological test by using the positive test as reference
(blue line) or the year 1996 (red and green lines for negative
and positive tests respectively) in the negative binomial model
of counts of parasitological tests.
Figure 5 Mean age of subjects with negative and positive parasitological tests during 1996-2009.
Brasseur et al. Malaria Journal 2011, 10:203
http://www.malariajournal.com/content/10/1/203
Page 6 of 10even across areas of stable malaria, depending on the
intensity of transmission [16].
While trends towards decreased malaria transmis-
sion, morbidity and mortality are being reported
world-wide [3-5,8], very little information exists on
how these changes affect different ages. In 2008,
O’Meara et al [4] reported that while the age of non-
malaria fevers seen at a paediatric word in Kilifi, Kenya
has remained unchanged between 1990-2007 (2.15 to
2.18 years), that of slide-positive patients increased
from 2.3 to 3.6 years. In Mlomp, the mean age of the
malaria patients increased steadily from 13.5 years in
1996 to 21.1 in 2010, while non-malaria fevers
remained stable (19.8 years in 2007 and 23.5 in 2010).
While overall in agreement with the trends presented
by O’Meara et al [4], the situation here is clearly
different from coastal Kenya where intensity of trans-
mission is higher, age of patients lower, and where the
curves of the malaria-positive and malaria-negative
hospital admissions started diverging already in the
1990s.
The challenge with these data was to translate an
observation into a statistically robust analysis of trends
over time, hence the use of models, which allow the
study of interactions between variables. All these ana-
lyses converge to show a progressive shift in the age-
dependent risk of malaria, with increasing risk for ado-
lescents and adults (16 years and older) with decreasing
malaria prevalence.
Between 1996 and 2010 significant changes have been
introduced to malaria policies and practices here like
elsewhere. In Senegal, the official policy change from
chloroquine or quinine given on clinical grounds to
artesunate-amodiaquine on parasitological confirmation
was made in 2006, but RDTs were made available from
2007. In Mlomp, parasitological diagnosis with micro-
scopy was applied occasionally in the 1990s and then
more systematically from 2000 when piloting the imple-
mentation of the new recommendations of the World
Health Organization [18] to use artemisinin-based com-
binations for parasitologically-confirmed malaria. In this
sense, Mlomp may be different from other settings in
the country and the changes seen here not be obvious
elsewhere, at least as yet. However, they indicate what
changes may be expected in other settings which have
been implementing these measures for a shorter period
of time. The decreased parasite-positive rates cannot be
ascribed to different performance of microscopy and
RDTs as this is regularly tested locally and no significant
discrepancies are found.
Table 3 Relative risk (RR) of positive malaria test by age classes during the period of 1997-2010 with respect to 1996
using a negative binomial model
0-5y 6-10y 11-15y 16-20y 21-30y > 30y
Year RR 95%CI RR 95%CI RR 95%CI RR 95%CI RR 95%CI RR 95%CI
1997 1.15 [0.91; 1.45] 1.35 [0.77; 2.35] 1.25 [0.71; 2.20] 1.35 [0.75; 2.44] 1.33 [0.74; 2.38] 1.13 [0.64; 1.99]
1998 0.68 [0.53; 0.86] 0.92 [0.52; 1.62] 0.65 [0.37; 1.17] 0.77 [0.42; 1.41] 0.62 [0.34; 1.13] 0.53 [0.29; 0.94]
1999 0.79 [0.62; 1.01] 1.28 [0.73; 2.24] 0.90 [0.51; 1.58] 0.80 [0.44; 1.47] 0.70 [0.39; 1.27] 0.60 [0.34; 1.08]
2000 1.05 [0.83; 1.33] 1.27 [0.72; 2.21] 0.99 [0.56; 1.74] 1.77 [0.99; 3.17] 1.38 [0.78; 2.47] 0.56 [0.31; 1.00]
2001 1.25 [0.98; 1.59] 1.44 [0.82; 2.52] 1.23 [0.70; 2.17] 1.36 [0.75; 2.46] 1.24 [0.69; 2.23] 1.13 [0.64; 2.00]
2002 0.59 [0.46; 0.75] 0.77 [0.43; 1.37] 0.69 [0.39; 1.24] 0.94 [0.51; 1.71] 0.76 [0.42; 1.39] 0.64 [0.36; 1.16]
2003 0.85 [0.67; 1.08] 1.16 [0.66; 2.03] 1.11 [0.63; 1.97] 1.45 [0.81; 2.62] 1.30 [0.72; 2.32] 1.21 [0.68; 2.14]
2004 0.50 [0.39; 0.64] 0.58 [0.32; 1.04] 0.55 [0.30; 0.99] 0.67 [0.36; 1.25] 0.66 [0.36; 1.21] 0.60 [0.33; 1.09]
2005 0.45 [0.35; 0.58] 0.57 [0.32; 1.02] 0.51 [0.28; 0.92] 0.70 [0.38; 1.30] 0.45 [0.24; 0.83] 0.40 [0.22; 0.73]
2006 0.25 [0.19; 0.33] 0.25 [0.14; 0.48] 0.26 [0.14; 0.50] 0.62 [0.32; 1.18] 0.38 [0.20; 0.73] 0.40 [0.21; 0.75]
2007 0.14 [0.11; 0.19] 0.22 [0.12; 0.42] 0.13 [0.07; 0.26] 0.31 [0.16; 0.61] 0.27 [0.14; 0.53] 0.23 [0.12; 0.45]
2008 0.10 [0.07; 0.14] 0.19 [0.10; 0.39] 0.16 [0.08; 0.32] 0.32 [0.16; 0.67] 0.26 [0.13; 0.53] 0.33 [0.17; 0.66]
2009 0.05 [0.04; 0.07] 0.10 [0.04; 0.22] 0.09 [0.04; 0.19] 0.14 [0.06; 0.33] 0.11 [0.05; 0.26] 0.13 [0.06; 0.28]
2010 0.03 [0.02; 0.04] 0.09 [0.04; 0.23] 0.06 [0.02; 0.17] 0.17 [0.07; 0.43] 0.14 [0.06; 0.36] 0.15 [0.06; 0.36]
Figure 7 Relative Risk (RR) for a positive parasitological test by
using the 0-5y age category as reference in the negative
binomial model of counts of parasitological tests.
Brasseur et al. Malaria Journal 2011, 10:203
http://www.malariajournal.com/content/10/1/203
Page 7 of 10A temporal association between the reduced malaria
risk and the availability of an effective treatment (artesu-
nate-amodiaquine) is apparent but there is no decisive
evidence of a causal relationship. Rainfalls cannot
explain the changes: they fluctuated overtime, but have
not decreased - if anything, there has been more preci-
pitations in 2008-2010 than in 1996-1998 (Figure 8).
Distribution, use and effects of bed nets are difficult to
q u a n t i f y .D a t af o rt h ee n t i r ec o u n t r y[ 1 9 ]r e p o r ta n
increase between 2005-2010 in the number of house-
holds with an impregnated bed net from 20% to 82%. In
2010, 45% of children under 5 and 35% of the 5-14 year
olds slept under a bed net, as compared to 25% and
31% of men aged 15-49 and adults over 50. More speci-
fically for Mlomp, records available at the district level
show that a total of 1,518 bed nets were distributed in
the period 2002-07 (308 in 2002, 200 in 2003, 165 in
2004, 500 in 2005, 60 in 2006 and 285 in 2007) for a
population of ~7,600. This does not include other provi-
ders (e.g. non-governmental organizations). A local
study (unpublished) found in 2010 that 48% of the
households interviewed utilise bed nets correctly. The
RBM report [19], local experience and other data [20]
concur that suboptimal use of bed nets occurs when the
“perceived benefits of reduction in mosquito nuisance
and [the risk] of malaria [are] considered not to be
worth the inconvenience of daily use”. While local data
are not available, the country data on lower utilisation
o fb e dn e t sb ya d u l t sm i g h tc o n t r i b u t et ot h er e l a t i v e
increase in risk of malaria observed in this setting.
Changes in users’ and health providers’ behaviours
may be possible. Attendance to the health facility has
decreased steadily overtime and consultations now are
~40-50% of those in the 1990’s .I tm a yb ea r g u e dt h a t
people are turning away from the dispensary. However,
this seems not to be the case as there is no private sec-
tor in the village and attendance to other facilities of the
district has not increased. Therefore, this may be a
result of less illness in the community. The number of
consultations which were not treated as malaria (on any
grounds) dropped and was in 2002-2006 circa half of
those seen in the 1990s, but started raising again and is
~80% in 2007-2010.
Comparing local data to the official data from the
national malaria control programme for the country is
not easy; country malaria statistics included in the past
both clinical and parasitological diagnoses; the wide-
scale implementation of parasitological diagnosis with
RDTs started in 2007. Mean malaria morbidity for the
Figure 8 Average yearly rain falls in Mlomp for the period
1996-2010.
Table 4 Relative risk (RR) of positive malaria test by age classes during the period of 1996-2010 with the age group 0-
5y as the reference using a negative binomial model
6-10y 11-15y 16-20y 21-30y > 30y
RR 95%CI RR 95%CI RR 95%CI RR 95%CI RR 95%CI
1996 0.82 [0.64; 1.03] 0.72 [0.57; 0.92] 0.35 [0.27; 0.45] 0.33 [0.26; 0.43] 0.39 [0.30; 0.50]
1997 0.96 [0.55; 1.68] 0.79 [0.45; 1.40] 0.41 [0.22; 0.76] 0.38 [0.21; 0.70] 0.38 [0.21; 0.68]
1998 1.11 [0.63; 1.94] 0.70 [0.39; 1.25] 0.40 [0.21; 0.74] 0.30 [0.16; 0.56] 0.30 [0.17; 0.54]
1999 1.31 [0.75; 2.30] 0.82 [0.46; 1.45] 0.35 [0.19; 0.66] 0.29 [0.16; 0.54] 0.30 [0.16; 0.53]
2000 0.98 [0.56; 1.71] 0.68 [0.38; 1.20] 0.59 [0.32; 1.08] 0.44 [0.24; 0.79] 0.21 [0.11; 0.37]
2001 0.94 [0.54; 1.64] 0.71 [0.40; 1.26] 0.38 [0.20; 0.70] 0.33 [0.18; 0.60] 0.35 [0.20; 0.63]
2002 1.07 [0.61; 1.89] 0.86 [0.48; 1.53] 0.56 [0.30; 1.03] 0.43 [0.23; 0.79] 0.43 [0.24; 0.77]
2003 1.11 [0.63; 1.94] 0.95 [0.53; 1.67] 0.59 [0.32; 1.10] 0.50 [0.28; 0.92] 0.55 [0.31; 0.98]
2004 0.94 [0.53; 1.68] 0.79 [0.44; 1.42] 0.47 [0.25; 0.88] 0.43 [0.23; 0.81] 0.47 [0.26; 0.85]
2005 1.03 [0.58; 1.83] 0.82 [0.46; 1.47] 0.55 [0.29; 1.02] 0.33 [0.18; 0.62] 0.35 [0.19; 0.63]
2006 0.83 [0.46; 1.51] 0.76 [0.41; 1.40] 0.86 [0.46; 1.63] 0.51 [0.27; 0.96] 0.62 [0.34; 1.14]
2007 1.25 [0.69; 2.26] 0.66 [0.36; 1.23] 0.75 [0.39; 1.44] 0.62 [0.33; 1.17] 0.62 [0.34; 1.16]
2008 1.58 [0.85; 2.95] 1.14 [0.60; 2.19] 1.13 [0.58; 2.24] 0.86 [0.44; 1.68] 1.29 [0.69; 2.42]
2009 1.57 [0.80; 3.08] 1.20 [0.60; 2.42] 0.97 [0.46; 2.03] 0.73 [0.35; 1.50] 0.98 [0.50; 1.91]
2010 2.61 [1.27; 5.39] 1.60 [0.74; 3.46] 2.03 [0.94; 4.39] 1.63 [0.77; 3.48] 1.96 [0.96; 4.01]
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and then dropped steadily to reach 7% in 2008 and 4%
in 2009. The total number of cases reported to the
national programme dropped from 1,555,310 in 2006
(clinical diagnosis) to 170,890 in 2009 (parasitological
diagnosis) (Ministère de la Santé et de la Prévention,
République du Sénégal 2010).
The total number of cases reported to the national
programme dropped from 1,550,000 in 2006 and
1,170,00 in 2007 (malaria suspected cases) to 295,000 in
2008 and 174,000 in 2009 (confirmed malaria cases)
[19]. A recent paper on national trends between 2007-
09 [21] also reports a drop in both the number of sus-
pected and confirmed cases, as well as the number of
treatments, after introducing RDTs country-wide. Of
note, on average throughout the country 86% of the sus-
pected cases were tested in 2009 and malaria infection
was detected in ~30%.
In summary, this study shows that, in this setting ori-
ginally with moderate malaria transmission, the risk of
malaria has decreased over time, with a redistribution of
the risk across ages, and that a similar change is not
observed for the non-malaria fevers. It is legitimate to
infer that less malaria is driving improvements in gen-
eral health in this community; when comparing the last
four years (2007-2010) to pre-2000 years, the drop in
malaria (estimated cases) was > 96%, which is compara-
tively much larger than the decrease in non-malaria
fevers (estimated) which dropped by 46% (54% for total
consultations for fever). Furthermore, effects of reduced
malaria and the possible interaction between malaria
and other febrile illnesses, especially in children, may
translate into long-term benefits that are difficult to
quantify with the information available at this stage.
Finally, over-treatment of malaria decreased with the
new policy.
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